Samah S. Khalil, Amany I. Ahmed, Nada A. Mohammed, Azza A. El-Naggar, Haytham A. Ali, Hamad R.E. Al-Saadawy


In the last few years, the metabolic syndrome (MetS) has attracted increased attention. Metabolic syndrome defined as a group of interconnected biochemical, physiological, metabolic and clinical risk factors such as hypertension, obesity, glucose intolerance, dyslipidemia and inflammation that  lead to many fatal diseases as atherosclerotic cardiovascular disease, stroke and type 2 diabetes mellitus. This review tends to go over the main points of the essential mechanisms involved in induction models of MetS by diet regimen based on high-fat high fructose/sucrose (HFHF) added to normal chow. Management of metabolic syndrome should undergo several axes such as increasing physical activity, modification of lifestyle and healthy food besides. Moreover, medications can be used to control the symptoms of different disease related to metabolic syndrome. Finally, we can conclude that the main and prevalent risk factors for the pathophysiology of Metabolic Syndrome are Insulin resistant, abdominal obesity. Also, physical inactivity and chronic inflammation which provide a possible explanation of the cause of the metabolic syndrome until now which designates the energetic relationship between a number of contributing factors.

Key words: metabolic syndrome; diabetes mellitus; insulin resistance; obesity

Full Text:



(1) Kaur J. A Comprehensive Review on Metabolic Syndrome. Cardiology Research and Practice. 2014.p: 1–21.

(2) Rampal S MS, Guallar E, Bulgiba A, Mohamed R, Rahmat R, et al. Ethnic differences in the prevalence of metabolic syndrome: results from a multi-ethnic population-based survey in Malaysia. PLoS One. 2012; 7: e46365.

(3) Ranasinghe P CD, Jayawardena R, Katulanda P. The influence of family history of hypertension on disease prevalence and associated metabolic risk factors among Sri Lankan adults. BMC Public Health 2015; 15: 576.

(4) Panchal SK Brown L. Rodent models for metabolic syndrome research. J Biomed Biotechnol. 2011; doi: 10.1155/2011/351982.

(5) Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, et al. Adipocyte fatty acid–binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clinical chemistry. 2006; 52: 405–13.

(6) O'neill S, O'driscoll L. Metabolic syndro-me: a closer look at the growing epidemic and its associated pathologies. Obesity reviews. 2015; 16: 1–12.

(7) Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009; 120: 1640–5.

(8) Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult US population, 1999–2010. Journal of the American College of Cardiology. 2013; 62: 697–703.

(9) Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care. 2005; 28: 2745–9.

(10) Waterhouse D, McLaughlin A, Sheehan F, O’Shea D. An examination of the prevalence of IDF-and ATPIII-defined metabolic syndrome in an Irish screening population. Irish journal of medical science. 2009; 178: 161–6.

(11) Zimmet PZ, Alberti KGM, Shaw JE. Mainstreaming the metabolic syndrome: a definitive definition. Medical Journal of Australia. 2005; 183: 176

(12) de Carvalho Vidigal F, Bressan J, Babio N, Salas-Salvadó J. Prevalence of metabolic syndrome in Brazilian adults: a systematic review. BMC public health. 2013; 13: doi: 10.1186/1471-2458-13-1198.

(13) van Vliet-Ostaptchouk JV, Nuotio M-L, Slagter SN, Doiron D, Fischer K, Foco L, et al. The prevalence of metabolic syndrome and metabo-lically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC endocrine disorders. 2014; 14: doi: 10.1186/1471-2458-13-1198.

(14) Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC public health. 2007; 7: 10.1186/1471-2458-7-220

(15) Balkau B, Vernay M, Mhamdi L, Novak M, Arondel D, Vol S, et al. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French DESIR study. Diabetes & Metabolism. 2003; 29: 526–32.

(16) Li R, Li W, Lun Z, Zhang H, Sun Z, Kanu JS, et al. Prevalence of metabolic syndrome in Mainland China: a meta-analysis of published studies. BMC public health. 2016; 16. doi: 10.1186/s12889-016-2870-y.

(17) Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES‐34). Diabetes/metabolism research and reviews. 2007; 23: 127–34.

(18) Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. The Journal of Clinical Endocrinology & Metabolism. 2008; 93s9-s30.

(19) Gujral UP, Narayan KV, Pradeepa RG, Deepa M, Ali MK, Anjana RM, et al. Comparing type 2 diabetes, prediabetes, and their associated risk factors in Asian Indians in India and in the US: the CARRS and MASALA studies. Diabetes Care. 2015; 38; 1312-8. doi: 10.2337/dc15-0032.

(20) Lee CMY, Huxley RR, Woodward M, Zimmet P, Shaw J, Cho NH, et al. Comparisons of metabolic syndrome definitions in four populations of the Asia-Pacific region. Metabolic syndrome and related disorders. 2008; 6: 37–46.

(21) Harzallah F, Alberti H, Ben Khalifa F. The metabolic syndrome in an Arab population: a first look at the new International Diabetes Federation criteria. Diabetic medicine. 2006; 23: 441–4.

(22) Gannar F, de León AC, Díaz BB, Pérez MCR, Rodríguez IM, Dahmen FB, et al. Social class and metabolic syndrome in populations from Tunisia and Spain. Diabetology & metabolic syndrome. 2015; 7: doi: 10.1186/s13098-015-0084-6.

(23) Lillioja S, Mott DM, Zawadzki JK, Young AA, Abbott WG, Knowler WC, et al. In vivo insulin action is familial characteristic in nondiabetic Pima Indians. Diabetes. 1987; 36: 1329–35.

(24) Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Mañas LR, et al. Metabolic syndrome across Europe: different clusters of risk factors. European journal of preventive cardiology. 2015; 22: 486-91.

(25) Zhao Y, Yan H, Yang R, Li Q, Dang S, Wang Y. Prevalence and determinants of metabolic syndrome among adults in a rural area of Northwest China. PloS one. 2014; 9: e91578.

(26) Friend A, Craig L, Turner S. The prevalence of metabolic syndrome in children: a systematic review of the literature. Metabolic syndrome and related disorders. 2013; 11: 71–80.

(27) Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Archives of pediatrics & adolescent medicine. 2003; 157: 821–7.

(28) Johnson WD, Kroon JJ, Greenway FL, Bouchard C, Ryan D, Katzmarzyk PT. Prevalence of risk factors for metabolic syndrome in adolescents: National Health and Nutrition Examination Survey (NHANES), 2001-2006. Archives of pediatrics & adolescent medicine. 2009; 163: 371–7.

(29) Alberti KGMM, Zimmet Pf. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic medicine. 1998; 15: 539–53.

(30) Balkau B, Charles M. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabetic medicine. 1999; 16: 442–3.

(31) Expert Panel on Detection E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–97.

(32) Einhorn M, FACP, FACE, Daniel. American College of Endocrinology position statement on the insulin resistance syndrome. Endocrine practice. 2003; 9 (2): 5–21.

(33) Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. The Lancet. 2005; 366: 1059–62.

(34) Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005; 112: 2735–52.

(35) Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. 2009; 120: 1640. doi: 10.1161/CIRCULATIONAHA.109.192644

(36) Mikkola I JJ, Timonen M, Härkönen P, Saastamoinen E, Laakso M, Peitso A, Juuti A-K, Keinänen-Kiukaanniemi S & Mäkinen T Physical activity and body composition changes during military service. Med Sci Sports Exerc. 2009; 41: 1735–42.

(37) Grundy SM CJ, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC,Jr, Spertus JA, Costa F, American Heart Association & National Heart, Lung, and Blood Institute.American Heart Association and National Heart, Lung, and Blood Institute Scientific Statement. Crit Pathw Cardiol 2005.4; 198–203

(38) Einhorn D RG, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA ,Wilson PW (2003). American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237–52.

(39) Rydén, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., De Boer, M.J., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K. and Priori, et al; . Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal,2007 28, p; 8–136.

(40) Lee L, Sanders RA. Metabolic Syndrome. Pediatrics in Review. 2012; 33: 459–68.

(41) Meigs JB, Nathan DM, Wolfsdorf JI, Mulder JE. The metabolic syndrome (insulin resistance syndrome or syndrome X). Available in www.UpToDate.com Accessed. 2015.

(42) Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. The Journal of clinical investigation. 2017; 114: 1752–61.

(43) Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice? The American journal of clinical nutrition. 2006; 83: 1248–51.

(44) Lemieux I, Pascot A, Prud’homme D, Alméras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arteriosclerosis, thrombosis, and vascular biology. 2001; 21: 961–7.

(45) Marcil V, Amre D, Seidman EG, Boudreau F, Gendron FP, Ménard D, et al. Hepatocyte nuclear factor 4 alpha polymorphisms and the metabolic syndrome in French-Canadian youth. PloS one. 2015; 10: e0117238.

(46) Petersen KF, Shulman GI. Etiology of insulin resistance. The American journal of medicine. 2006; 119: S10–S6.

(47) ter Horst KW, van Galen KA, Gilijamse PW, Hartstra AV, de Groot P, van der Valk F, et al. Methods for quantifying adipose tissue insulin resistance in overweight/obese humans. Interna-tional Journal of Obesity. 2017; 41-1294.

(48) Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. The American journal of medicine. 2007; 120: S12–S8.

(49) Naiberg M, Newton D, Collins J, Dickstein D, Bowie C, Goldstein B. Elevated triglycerides are associated with decreased executive function among adolescents with bipolar disorder. Acta Psychiatrica Scandinavica. 2016; 134: 241–8.

(50) Després JP. Is visceral obesity the cause of the metabolic syndrome? Annals of medicine. 2006; 38: 52–63.

(51) Mittelman SD, Van Citters GW, Kirkman EL, Bergman RN. Extreme insulin resistance of the central adipose depot in vivo. Diabetes. 2002; 51: 755–61.

(52) Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metabolism. 2007; 5: 237–52.

(53) Kim Y-B, Kotani K, Ciaraldi TP, Henry RR, Kahn BB. Insulin-stimulated protein kinase C λ/ζ activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes. 2003; 52: 1935–42.

(54) Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. The Lancet. 2010; 375: 2267–77.

(55) Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37.S81–S90.

(56) Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome—a new world‐wide definition. A consensus statement from the international diabetes federation. Diabetic medicine. 2006; 23: 469–80.

(57) Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018; 41; S13-S27.

doi: 10.1038/nrdp.2015.19

(58) DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nature reviews Disease Pimers. 2015; 1: doi: 10.1038/nrdp.2015.19.

(59) Eapen D, Kalra GL, Merchant N, Arora A, Khan BV. Metabolic syndrome and cardiovascular disease in South Asians. Vascular Health and Risk Management. 2009; 5: 731–43.

(60) Urakawa H, Katsuki A, Sumida Y, Gabazza EC, Murashima S, Morioka K, et al. Oxidative stress is associated with adiposity and insulin resistance in men. The Journal of Clinical Endocrinology & Metabolism. 2003; 88: 4673–6.

(61) Akram M, Hamid A. Mini review on fructose metabolism. Obesity research & clinical practice. 2013; 7: e89-e94.

(62) Holvoet P, Lee D-H, Steffes M, Gross M, Jacobs DR. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. Jama. 2008; 299: 2287–93.

(63) Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arteriosclerosis, thrombosis, and vascular biology. 2004; 24: 816–23.

(64) Hopps E, Noto D, Caimi G, Averna M. A novel component of the metabolic syndrome: the oxidative stress. Nutrition, Metabolism and Cardiovascular Diseases. 2010; 20: 72–7.

(65) Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice. 2014; 105: 141–50.

(66) Chawla A, Nguyen KD, Goh YS. Macrophage-mediated inflammation in metabolic disease. Nature Reviews Immunology. 2011; 11: 738–49.

(67) Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. The Journal of clinical investigation. 2006; 116: 1793–801.

(68) Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. The Lancet. 2005; 365: 1415–28.

(69) Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988; 37: 1595–607.

(70) Hegele RA, Pollex RL. Genetic and physiological insights into the metabolic syndrome. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2005; 289: R663-R9.doi; 10.1152/ajpregu.00275.2005.

(71) Sutton BS, Weinert S, Langefeld CD, Williams AH, Campbell JK, Saad MF, et al. Genetic analysis of adiponectin and obesity in Hispanic families: the IRAS Family Study. Human genetics. 2005; 117: 107–18.

(72) Salminen LE, Schofield PR, Pierce KD, Zhao Y, Luo X, Wang Y, et al. Neuromarkers of the common angiotensinogen polymorphism in healthy older adults: a comprehensive assessment of white matter integrity and cognition. Behavioural brain research. 2016; 296: 85–93.

(73) Sofat R, Cooper JA, Kumari M, Casas JP, Mitchell JP, Acharya J, et al. Circulating apolipoprotein E concentration and cardiovascular disease risk: meta-analysis of results from three studies. PLoS medicine. 2016; 13: e1002146.

(74) Cheng S, Pang B, Gu C, Sun S-P, An C, Zhang Z-P, et al. Association between apolipoprotein C3 gene promoter polymorphisms and fasting triglyceride level: A meta-analysis. Frontiers in Laboratory

Medicine. 2017; 1: 151–7.

(75) Kaya Z, Caglayan S, Akkiprik M, Aral C, Ozisik G, Ozata M, et al. Impact of glucocorticoid receptor gene (NR3C1) polymorphisms in Turkish patients with metabolic syndrome. Journal of endocrinological investigation. 2016; 39: 557–66.

(76) Siffert W. G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med. 2005; 56: 17–28.

(77) Xue Y, Cao R, Nilsson D, Chen S, Westergren R, Hedlund E-M, et al. FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proceedings of the National Academy of Sciences. 2008; 105: 10167–72.

(78) Basciano H, Federico L, Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutrition & metabolism. 2005; 2: 5.

doi: 10.1186/1743-7075-2-5.

(79) Liao C, Gao W, Cao W, Lv J, Yu C, Wang S, et al. Associations Between Obesity Indicators and Blood Pressure in Chinese Adult Twins. Twin Research and Human Genetics. 2017; 20: 28–35.

(80) Lin H-F, Boden-Albala B, Juo S, Park N, Rundek T, Sacco R. Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. Diabetologia. 2005; 48: 2006–12.

(81) Austin MA, Edwards KL, McNeely MJ, Chandler WL, Leonetti DL, Talmud PJ, Humphries SE, Fujimoto WY. Heritability of multivariate factors of the metabolic syndrome in nondiabetic Japanese Americans. Diabetes. 2004 ; 53: 1166–9.

(82) Pollex RL, Hegele RA. Genetic determinants of the metabolic syndrome. Nature Reviews Cardiology. 2006; 3: 482–9.

(83) Panchal SK PH, Iyer A, Nazer R, Alam A, Diwan V, Kauter K, Sernia C, Campbell F, Ward L, Gobe G. High-carbohydrate high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. Journal of cardiovascular pharmacology. 2011; 57: 51–64.

(84) Ghezzi AC, Cambri LT, Botezelli JD, Ribeiro C, Dalia RA, de Mello MAR. Metabolic syndrome markers in Wistar rats of different ages. Diabetology & metabolic syndrome. 2012; 4: 16. doi: 10.1186/1758-5996-4-16.

(85) Suman RK, Ray Mohanty I, Borde MK, Maheshwari U, Deshmukh Y. Development of an experimental model of diabetes co-existing with metabolic syndrome in rats. Advances in pharmacological sciences. 2016. doi: 10.1155/2016/9463476.

(86) Warden CH, Fisler JS. Comparisons of diets used in animal models of high fat feeding. Cell Metabolism. 2008; 7.

doi: 10.1016/j.cmet.2008.03.014

(87) Castro MC, Massa ML, Del Zotto H, Gagliardino JJ, Francini F. Rat liver uncoupling protein 2: changes induced by a fructose-rich diet. Life sciences. 2011; 89: 609–14.

(88) de Castro UGM, Silva ME, de Lima WG, Campagnole-Santos MJ, Alzamora AC. Age-dependent effect of high-fructose and high-fat diets on lipid metabolism and lipid accumulation in liver and kidney of rats. Lipids in health and disease. 2013; 12. doi: 10.1186/1476-511X-12-136

(89) Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension (Dallas, Tex : 1979). 1987; 10: 512–6.

(90) BuÑag RD, Tomita T, Sasaki S. Chronic sucrose ingestion induces mild hypertension and tachycardia in rats. Hypertension. 1983; 5: 218–25.

(91) Buettner R SJ, Bollheimer LC. High‐fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity. 2007; 15: 798–808.

(92) Yang ZH, Miyahara H, Takeo J, Katayama M. Diet high in fat and sucrose induces rapid onset of obesity-related metabolic syndrome partly through rapid response of genes involved in lipogenesis, insulin signalling and inflammation in mice. Diabetology & metabolic syndrome. 2012.4; doi: 10.1186/1758-5996-4-32

(93) Panchal SK, Brown L. Rodent models for metabolic syndrome research. BioMed Research International. 2010; doi: 10.1155/2011/351982.

(94) Mooren FC. Encyclopedia of exercise medicine in health and disease: SpringerLink (Online service); 2012; P147–229.

(95) Fujita Y, Maki K. High-fat diet-induced obesity triggers alveolar bone loss and spontaneous periodontal disease in growing mice. BMC obesity. 2015; 3: 1 doi: 10.1186/s40608-016-0082-8.

(96) Parks EJ, Skokan LE, Timlin MT, Dingfelder CS. Dietary sugars stimulate fatty acid synthesis in adults. The Journal of Nutrition. 2008; 138: 1039–46.

(97) Lozano I, Van der Werf R, Bietiger W, Seyfritz E, Peronet C, Pinget M, et al. High-fructose and high-fat diet-induced disorders in rats: impact on diabetes risk, hepatic and vascular compli-cations. Nutrition & Metabolism. 2016; 13: 15.

(98) Rizkalla SW. Health implications of fructose consumption: A review of recent data. Nutrition & Metabolism. 2010; 7: 82.

(99) Lowndes J, Sinnett S, Pardo S, Nguyen VT, Melanson KJ, Yu Z, et al. The effect of normally consumed amounts of sucrose or high fructose corn syrup on lipid profiles, body composition and related parameters in overweight/obese subjects. Nutrients. 2014; 6: 1128–44.

(100) Jürgens H, Haass W, Castaneda TR, Schürmann A, Koebnick C, Dombrowski F, et al. Consuming fructose‐sweetened beverages increases body adiposity in mice. Obesity research. 2005; 13: 1146–56.

trics: Springer Science & Business Media; 2011; p707–711

(102) Pradeepa R, Prabhakaran D, Mohan V. Emerging economies and diabetes and cardiovascular disease. Diabetes technology & therapeutics. 2012 ; 1; 14: S-59..

(103) Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. Journal of Biological Chemistry. 2007; 282: 36275–82.

(104) Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease–. The American journal of clinical nutrition. 2007; 86: 285–300.

(105) Xu F, Du Y, Hang S, Chen A, Guo F, Xu T. Adipocytes regulate the bone marrow microenvironment in a mouse model of obesity. Molecular medicine reports. 2013; 8: 823–8.

(106) Grosso G, Mistretta A, Frigiola A, Gruttadauria S, Biondi A, Basile F, et al. Mediterranean Diet and Cardiovascular Risk Factors: A Systematic Review. Critical Reviews in Food Science and Nutrition. 2014; 54: 593–610.

(107) Dubé JJ, Sitnick MT, Schoiswohl G, Wills RC, Basantani MK, Cai L, et al. Adipose triglyceride lipase deletion from adipocytes, but not skeletal myocytes, impairs acute exercise performance in mice. American Journal of Physiology-Endocrinology and Metabolism. 2015; 308: E879–E90.

(108) Grundy SM, Hansen B, Smith Jr SC, Cleeman JI, Kahn RA, Participants C. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004; 109: 551–6.

(109) Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine. 2001; 344: 1343–50.

(110) Pyörälä K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 2004; 27: 1735–40.

(111) Rubins HB. Triglycerides and coronary heart disease: implications of recent clinical trials. Journal of cardiovascular risk. 2000; 7: 339–45.

(112) Madhu SV, Saboo B, Makkar BM, Reddy GC, Jana J, Panda JK, Singh J, Setty N, Rao PV, Chawla R, Sahay RK. RSSDI clinical practice recommendations for management of type 2 diabetes mellitus, 2015. International Journal of Diabetes in Developing Countries. 2015 ; 35: 1–71.

(113) Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Molecular aspects of Medicine. 2006; 27: 1–93.

DOI: http://dx.doi.org/10.26873/SVR-670-2018


  • There are currently no refbacks.